HealthcareServices

Neurological Biomarkers Market Performance Outlook 2026–2030: Revenue to Hit $22.81 Billion at 14% CAGR

February 27, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the neurological biomarkers market from 2026–2035 with trusted insights from The Business Research Company

What long-term size projections exist for the Neurological Biomarkers Market covering 2026–2035?_x000D_

The neurological biomarkers market has seen significant expansion in recent years. It is anticipated to expand from $11.92 billion in 2025 to $13.52 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 13.4%. The increase observed in previous periods is largely due to factors such as the rising prevalence of neurological disorders, the early development of protein biomarkers, the increased use of imaging biomarkers, the growing adoption of DNA biomarkers, and the initial integration of biomarkers in clinical trials._x000D_

_x000D_

The neurological biomarkers market is projected for swift expansion in the coming years. Its valuation is set to reach $22.82 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 14.0%. This anticipated growth stems from factors such as the broadening application of personalized medicine utilizing biomarkers, an increasing need for metabolomics biomarkers, enhanced investment in CNS drug development, the evolution of advanced diagnostic platforms, and the expanding implementation of biomarker-led disease surveillance. Key trends predicted for this period encompass the escalating role of biomarkers in early neurological detection, greater incorporation of proteomic and genomic biomarkers, the wider use of imaging biomarkers for CNS disorder assessment, an increasing requirement for biomarkers within drug development processes, and a heightened clinical emphasis on biomarker testing for neurodegenerative conditions._x000D_

_x000D_

#Access Your Free Sample Report for In-Depth Market Insights:#_x000D_

https://www.thebusinessresearchcompany.com/sample.aspx?id=12677&type=smp_x000D_

_x000D_

Which Drivers Are Impacting The Competitive Landscape Of The Neurological Biomarkers Market?_x000D_

The neurological biomarker market is expected to grow due to the increasing occurrence of neurological diseases. These illnesses affect the brain, spinal cord, and all other nerves throughout the body. For example, Parkinson’s disease is a neurodegenerative disorder impacting the neurological system and parts of the body controlled by nerves. Neurological biomarkers aid in providing an early diagnosis for Parkinson’s disease through pathological, biochemical, and genetic testing. This trend is further supported by data from October 2023, when the World Federation of Neurology, a UK-based charity, reported that neurological disorders now rank as the second-leading cause of death and the primary cause of disability globally, reflecting an accelerating health burden. In 2023, over 40 percent of the global population was affected, and the number of individuals living with brain disease is projected to nearly double by 2050. Therefore, the increasing prevalence of neurological diseases is a key driver for the growth of the neurological biomarker market._x000D_

_x000D_

What Leading Segments Are Studied In The Neurological Biomarkers Market?_x000D_

The neurological biomarkers market covered in this report is segmented –_x000D_

_x000D_

1) By Product: Proteomics Biomarker, Genomics Biomarker, Metabolomics Biomarker, Imaging Biomarker, Other Products_x000D_

2) By Application: Alzheimer’s Disease, Parkinson’s Disease, Huntington’s Disease, Schizophrenia, Depression, Multiple Sclerosis, Spinal Muscular Atrophy_x000D_

3) By End-User: Hospital Laboratories, Clinical Diagnostic Centers, Research Organizations, Other End-Users_x000D_

_x000D_

Subsegments:_x000D_

1) By Proteomics Biomarker: Protein Biomarkers, Antibody Biomarkers_x000D_

2) By Genomics Biomarker: DNA Biomarkers, RNA Biomarkers_x000D_

3) By Metabolomics Biomarker: Metabolite Biomarkers, Lipid Biomarkers_x000D_

4) By Imaging Biomarker: MRI Biomarkers, PET Scan Biomarkers_x000D_

5) By Other Products: Neuroinflammatory Biomarkers, Neurotransmitter Biomarkers_x000D_

_x000D_

Which Trends Are Shaping Activity Within The Neurological Biomarkers Market?_x000D_

Major companies operating in the neurological biomarkers market are developing new products, such as advanced biomarker blood tests, to gain a competitive edge. Biomarker blood tests involve the analysis of specific molecules or indicators within the blood that provide information about a biological condition, disease, or physiological process. For instance, in July 2023, Quanterix Corporation, a US-based company specializing in the development and commercialization of ultra-sensitive digital immunoassay platforms, launched the LucentAD biomarker blood test. The LucentAD test is intended to assist medical professionals in evaluating patients who exhibit cognitive symptoms aligning with preliminary indications of alzheimer’s disease. This test quantifies levels of p-Tau 181, which has been demonstrated to be a biomarker of the pathophysiology of alzheimer’s disease (AD). When an adult is being tested for AD 1 and has cognitive impairment, the LucentAD test findings are meant to be utilized as a diagnostic tool. The test is not meant to be used as a stand-alone screening or diagnostic assay and it must be used in conjunction with other diagnostic tools._x000D_

_x000D_

Which Key Market Players Are Investing In Expansion And Innovation Within The Neurological Biomarkers Market?_x000D_

Major companies operating in the neurological biomarkers market are Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., Novartis AG, Thermos Fisher Scientific Inc., AstraZeneca Plc, Abbott Laboratories, Boehringer Ingelheim International GmbH, Becton Dickinson and Company, Agilent Technologies Inc., Grifols S.A., Eisai Co. Ltd., PerkinElmer Inc., Illumina Inc., Shimadzu Corporation, Waters Corporation, Bio-Rad Laboratories Inc., Mallinckrodt Plc, Qiagen N.V., Luminex Corporation, Siemens Healthineers, Olink Proteomics, Meso Scale Diagnostics, Quanterix Corp., Fujirebio, Cisbio Bioassays SAS, NeuroVision Imaging, Proteome Sciences Plc, Acumen Pharmaceuticals._x000D_

_x000D_

#Access The Complete Report For Deeper Market Insights:#_x000D_

https://www.thebusinessresearchcompany.com/report/neurological-biomarkers-global-market-report_x000D_

_x000D_

Which Regions Are Projected To Dominate The Neurological Biomarkers Market In The Coming Years?_x000D_

North America was the largest region in the neurological biomarkers market in 2025. The regions covered in the neurological biomarkers market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa._x000D_

_x000D_

#Request Your Customized Neurological Biomarkers Market Research Report for Competitive Advantage:#_x000D_

https://www.thebusinessresearchcompany.com/customise?id=12677&type=smp_x000D_

_x000D_

#Browse Through More Reports Similar to the Global Neurological Biomarkers Market 2026, By The Business Research Company#_x000D_

_x000D_

Biomarkers Market Report 2026_x000D_

https://www.thebusinessresearchcompany.com/report/biomarkers-global-market-report_x000D_

_x000D_

Central Nervous System Biomarkers Market Report 2026_x000D_

https://www.thebusinessresearchcompany.com/report/central-nervous-system-biomarkers-global-market-report_x000D_

_x000D_